Corcept Therapeutics Incorporated
Price Action
Technical Summary
CONSOLIDATINGCorcept Therapeutics Incorporated is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings contraction of 276% provides fundamental context to the price action. However, price is extended 34% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $74.51 | +6.98% | ABOVE |
| 50 SMA | $59.69 | +33.55% | ABOVE |
| 100 SMA | $48.67 | +63.79% | ABOVE |
| 150 SMA | $54.26 | +46.90% | ABOVE |
| 200 SMA | $60.00 | +32.84% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CORT in an uptrend right now?
CORT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CORT overbought or oversold?
CORT's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CORT outperforming the market?
CORT has a Relative Strength (RS) Rating of 91 out of 99. Yes, CORT is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is CORT in its 52-week range?
CORT is trading at $79.71, which is 88% of its 52-week high ($91.00) and 82% above its 52-week low ($28.66).
How volatile is CORT?
CORT has a Beta of 1.94 and 52-week volatility of 77%. It's more volatile than the S&P 500 - expect bigger swings.